Trial · NCT00112489

Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer

NCT00112489, Phase 2, Completed, Gynecologic Oncology Group; results first posted 2014-05-12

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer. Trials, record NCT00112489. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00112489

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer
NCT number: NCT00112489
Status: Completed
Phases: Phase 2
Enrollment: 55 participants, actual
Lead sponsor: Gynecologic Oncology Group
Conditions: Sarcoma
Interventions: carboplatin, paclitaxel
First posted: 2005-06-03
Last updated: 2018-09-25
Results first posted: 2014-05-12

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Nature and Degree of Toxicity	During study treatment and up to 30 days after stopping study treatment	Number of patients who experienced grade 1 or higher serious adverse event (term or group) regardless of attribution using CTCAE v3.0
Primary	Response Evaluation Criteria in Solid Tumors Criteria (RECIST) 1.0 Best Response	Response was measured every other cycle (q 6 weeks) until disease progression is documented.	Primary outcome measured according to RECIST v1.0 Best Response: Complete Response (CR) is disappearance of all target and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart Disease Progression is at least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD or the appearance of new lesions within 8 weeks of study entry. Partial Response (PR) is at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be no unequivocal progression of nontarget lesions and no new lesions. Documentation by two disease assessments at least 4 weeks apart is required Stable Disease is any condition not meeting the above criteria. Indeterminate is defined as having no repeat tumor assessments following initiation of study therapy for reasons unrelated to symptoms or signs of disease.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Nature and Degree of Toxicity	During study treatment and up to 30 days after stopping study treatment	Eligible and Evaluable patients	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Response Evaluation Criteria in Solid Tumors Criteria (RECIST) 1.0 Best Response	Response was measured every other cycle (q 6 weeks) until disease progression is documented.	Total eligible and treated participants	participants	NUMBER

Source ClinicalTrials.gov

Results by group209

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Nature and Degree of Toxicity	Grade 0	Leukopenia	2	Participants
Nature and Degree of Toxicity	Grade 1 (CTCAE v 3.0)	Leukopenia	4	Participants
Nature and Degree of Toxicity	Grade 2 (CTCAE v 3.0)	Leukopenia	20	Participants
Nature and Degree of Toxicity	Grade 3 (CTCAE v 3.0)	Leukopenia	19	Participants
Nature and Degree of Toxicity	Grade 4 (CTCAE v 3.0)	Leukopenia	1	Participants
Nature and Degree of Toxicity	Grade 5 (CTCAE v.3.0)	Leukopenia	0	Participants
Nature and Degree of Toxicity	Grade 0	Neutropenia	1	Participants
Nature and Degree of Toxicity	Grade 1 (CTCAE v 3.0)	Neutropenia	3	Participants
Nature and Degree of Toxicity	Grade 2 (CTCAE v 3.0)	Neutropenia	3	Participants
Nature and Degree of Toxicity	Grade 3 (CTCAE v 3.0)	Neutropenia	19	Participants

1 to 10 of 209Source ClinicalTrials.gov

See all 209 results by group

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Paclitaxel Followed by Carboplatin	55
Overall Study	COMPLETED	Paclitaxel Followed by Carboplatin	15
Overall Study	NOT COMPLETED	Paclitaxel Followed by Carboplatin	40

Source ClinicalTrials.gov

Adverse events60

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Leukopenia	Blood and lymphatic system disorders	Paclitaxel Followed by Carboplatin	40	46
other	Neutropenia	Blood and lymphatic system disorders	Paclitaxel Followed by Carboplatin	43	46
other	Thrombocytopenia	Blood and lymphatic system disorders	Paclitaxel Followed by Carboplatin	10	46
other	Anemia	Blood and lymphatic system disorders	Paclitaxel Followed by Carboplatin	32	46
other	Other Hematologic	Blood and lymphatic system disorders	Paclitaxel Followed by Carboplatin	3	46
other	Allergy	Immune system disorders	Paclitaxel Followed by Carboplatin	3	46
other	Auditory	Ear and labyrinth disorders	Paclitaxel Followed by Carboplatin	3	46
other	Cardiovascular	Cardiac disorders	Paclitaxel Followed by Carboplatin	4	46
other	Coagulation	Vascular disorders	Paclitaxel Followed by Carboplatin	1	46
other	Constitutional	General disorders	Paclitaxel Followed by Carboplatin	5	46

1 to 10 of 60Source ClinicalTrials.gov

See all 60 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Paclitaxel Followed by Carboplatin
Total, other adverse events	Paclitaxel Followed by Carboplatin	46	46
Total, serious adverse events	Paclitaxel Followed by Carboplatin	11	46

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
20421537	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00112489

GET https://conductscience.org/api/trials/v1/NCT00112489/results?page=2

API reference For AI assistants